On Wednesday 5 October 2016, at the Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Professor Umberto D'Alessandro (MRC Unit The Gambia,MRCG), Profes

In a ceremony held in Gaborone, Botswana, Dr Assan Jaye was one of 38 international Scientist honoured and recognised by the Academy of Sciences (AAS) as a Fellow in July 2016.

Group B Streptococcus (GBS) infection is a major cause of morbidity and mortality in infants. The major risk factor for GBS disease is maternal and later infant colonisation.

Christine Bartram is a PhD student currently involved in data collection at Keneba for the psycho-social measures in the BRain Imaging in Global HealTh BRIGHT study.

Dr Jane Achan is the coordinator of the malaria group within the Disease Control and Elimination Theme.

The World Health Organisation has pre-qualified Pfizer’s new four-dose, multi-dose vial (MDV) presentation of Prevenar 13®*, based on the results of a study conducted by MRC Unit The Gambia (MRCG)

“The first of its kind in Keneba” according to the feedback received from people who came from all over the surrounding villages in West Kiang to find out more about MRCG

The Development of Electronic Medical Records System (EMRS) for MRC Unit The Gambia Clinical Services Department (CSD) project is a major project milestone which serves as a tool to aid physicians

Originally from Nigeria, trained paediatrician and  clinical trial coordinator, Dr Idoko has worked at MRC Unit The Gambia since June 2010 (following a 1-year stint between Jul 2007 and Jul 2008).

Numerous risk factors can impact on a child’s brain development in the early years of life and most critically in the first 24 months.

Although malaria still contributes significantly to both morbidity and mortality in sub-Saharan Africa, the last decade has seen major progress in the fight against malaria as the burden has substa

The European Medicines Agency (EMA) have approved a new multi-dose preparation of Prevenar 13®, sponsored by biopharmaceutical company Pfizer, based on a study conducted by MRC Unit The Gambia.The